Breaking New Ground in Alzheimer’s Treatment: A Deep Dive into Lilly’s Kisunla™ (Donanemab-azbt) FDA Approval
July 16, 2024
The recent FDA approval of Lilly’s Kisunla™ (donanemab-azbt) for early symptomatic Alzheimer’s disease marks a monumental breakthrough in combating this debilitating condition. As we celebrate this achievement, it’s crucial to explore its implications and highlight how our innovative humanized mouse models contribute to advancing Alzheimer’s research. Kisunla™ targets the amyloid plaques that accumulate in the […]
